- Home
- ACAD vs MSGS Comparison
ACAD vs MSGS Comparison
Compare ACAD & MSGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- MSGS
- Stock Information
- Founded
- ACAD 1993
- MSGS 1879
- Country
- ACAD United States
- MSGS United States
- Employees
- ACAD N/A
- MSGS N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- MSGS Services-Misc. Amusement & Recreation
- Sector
- ACAD Health Care
- MSGS Consumer Discretionary
- Exchange
- ACAD Nasdaq
- MSGS Nasdaq
- Market Cap
- ACAD 4.3B
- MSGS 4.9B
- IPO Year
- ACAD 2004
- MSGS N/A
- Fundamental
- Price
- ACAD $23.61
- MSGS $212.91
- Analyst Decision
- ACAD Buy
- MSGS Buy
- Analyst Count
- ACAD 21
- MSGS 6
- Target Price
- ACAD $29.30
- MSGS $258.83
- AVG Volume (30 Days)
- ACAD 1.9M
- MSGS 188.7K
- Earning Date
- ACAD 11-05-2025
- MSGS 10-31-2025
- Dividend Yield
- ACAD N/A
- MSGS N/A
- EPS Growth
- ACAD 615.00
- MSGS N/A
- EPS
- ACAD 1.33
- MSGS N/A
- Revenue
- ACAD $1,018,885,000.00
- MSGS $1,039,220,000.00
- Revenue This Year
- ACAD $14.01
- MSGS N/A
- Revenue Next Year
- ACAD $11.72
- MSGS $4.68
- P/E Ratio
- ACAD $17.82
- MSGS N/A
- Revenue Growth
- ACAD 14.41
- MSGS 1.18
- 52 Week Low
- ACAD $13.40
- MSGS $173.26
- 52 Week High
- ACAD $26.65
- MSGS $237.99
- Technical
- Relative Strength Index (RSI)
- ACAD 39.78
- MSGS 71.79
- Support Level
- ACAD $23.70
- MSGS $204.29
- Resistance Level
- ACAD $25.90
- MSGS $210.26
- Average True Range (ATR)
- ACAD 0.74
- MSGS 3.53
- MACD
- ACAD -0.33
- MSGS 1.97
- Stochastic Oscillator
- ACAD 8.16
- MSGS 97.12
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.